Viatris to Participate in Upcoming Investor Conferences

PITTSBURGH, Oct. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in November 2025.

The Company will participate in a fireside chat at the UBS Global Healthcare Conference 2025 on November 11, 2025, at 8:45 a.m. ET.

In addition, the Company will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 11:30 a.m. GMT / 6:30 a.m. ET.

Investors and the general public are invited to listen to both sessions at their respective times at investor.viatris.com. An archived version of each session will be available following the live event and can be accessed at the same location for a limited time.

About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-to-participate-in-upcoming-investor-conferences-302581460.html

SOURCE Viatris Inc.